| CAS | 262438-43-7 |
| Sequence | Ac-Pro-His-Ser-Cys-Asn-NH2 |
| Sequence Single | Ac-PHSCN-NH2 |
| Molecular Formula | C23H35N9O8S |
| Molecular Weight | 597.65 |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Description | ATN 161 is a α5β1 integrin receptor antagonist. ATN 161 reduces liver metastasis and improves survival in combination with 5-FU in a mouse model of colon cancer. ATN 161 reduces MLL tumor growth in rats and decreases tumor volume of human MDA-MB-231 cell xenografts in mice. |
| References | 1. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Livant et al (2000). Cancer Res. 60 309 PMID: 10667582 2. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Khalili et al (2006). Mol.Cancer Ther. 5 2271 PMID: 16985061 3. Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Stoeltzing et al (2003). Int.J.Cancer. 104 496 PMID: 12584749 4. The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo. Wang W, et al. Invest Ophthalmol Vis Sci. 2011 Sep 14;52(10):7213-20. |